Omico helps advance precision oncology research through fast-tracked molecular and genomic screening, drawing on a nationally screened patient population that continues to grow.
We also provide access to a national network of researchers, clinicians, thought leaders and experts, helping researchers collaborate, expand capabilities and translate discoveries into better cancer care.
Perform intellectually-stimulating world-class research.
Access patient-focused opportunities that can change cancer care and transform lives.
Access state-of-the-art genomics and correlative science resources.
Join and collaborate with a national network of thought leaders.
Traditionally, biomarker screening is performed in each individual clinical trial. This inefficient method contributes significant costs to running a clinical trial, costing in the region of AUD $10M to identify 200 trial participants.
CGP is a next-generation screening approach that looks for hundreds of cancer biomarkers for multiple trials all at the same time. This more efficient method costs in the region of AUD $10 M to identify 400 trial participants for multiple clinical trials, a significant cost saving.
